FDA reverses course on rejection of Moderna's mRNA flu vaccine
regulatory response
investigated
The US Food and Drug Administration (FDA) has reversed its prior rejection decision regarding Moderna's mRNA flu vaccine, now allowing its progression through regulatory channels.
This matters because regulatory agencies adapting their stance on innovative vaccine technologies can accelerate their adoption, reshape pharmaceutical landscapes, and unlock significant public health and economic value by overcoming initial bureaucratic barriers.
1
Analysis
2
Screen
3
Fact Check
4
Synthesis